机构：[1]Department of Cardiothoracic Surgery, Panzhihua Central Hospital, 617000 Panzhihua, China[2]Department of Pathology, Sichuan Cancer Hospital, 610041 Chengdu, China四川省肿瘤医院[3]The Medical Department, The State Key Laboratory of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Diagnostics Co., Ltd, Nanjing Simcere Medical Laboratory Science Co., Ltd, 210002 Nanjing, China
Genomic fusions of anaplastic lymphoma kinase (ALK) are a well-established therapeutic target in non-small-cell lung cancer (NSCLC). Although various ALK fusion variants have been identified in NSCLC, their responses to ALK tyrosine-kinase inhibitors (TKIs) are heterogeneous. We report the case of a 71-year-old female patient diagnosed with lung adenocarcinoma with liver metastases. A novel CTNND1 (exon 14)-ALK (exon 20) fusion was identified from the biopsy sample by next-generation sequencing (NGS) and validated by immunohistochemistry (IHC) staining. Alectinib was administered, and the patient soon achieved partial response (PR). The progression-free survival (PFS) exceeded 15 months as of January 25, 2022. Our findings expand the spectrum of ALK rearrangements and provide a potential treatment option for lung adenocarcinoma patients with CTNND1-ALK fusions.
第一作者机构：[1]Department of Cardiothoracic Surgery, Panzhihua Central Hospital, 617000 Panzhihua, China
通讯作者：
推荐引用方式(GB/T 7714)：
Tian Xiang,Liao Qiong,Yang Qidong,et al.A novel alectinib-sensitive CTNND1-ALK fusion in a lung adenocarcinoma patient: a case report[J].INVESTIGATIONAL NEW DRUGS.2022,40(4):850-853.doi:10.1007/s10637-022-01245-3.
APA：
Tian, Xiang,Liao, Qiong,Yang, Qidong,Chen, Lin,Xiao, Mingzhe&Cheng, Yuanjian.(2022).A novel alectinib-sensitive CTNND1-ALK fusion in a lung adenocarcinoma patient: a case report.INVESTIGATIONAL NEW DRUGS,40,(4)
MLA：
Tian, Xiang,et al."A novel alectinib-sensitive CTNND1-ALK fusion in a lung adenocarcinoma patient: a case report".INVESTIGATIONAL NEW DRUGS 40..4(2022):850-853
